About the Authors
- Anna-Maija Tolppanen
-
* E-mail: anna-maija.tolppanen@uef.fi
Affiliations School of Pharmacy, University of Eastern Finland, Kuopio, Finland, Research Centre for Comparative Effectiveness and Patient Safety (RECEPS), University of Eastern Finland, Kuopio, Finland
- Ari Voutilainen
-
Affiliation Department of Nursing Science, University of Eastern Finland, Kuopio, Finland
- Heidi Taipale
-
Affiliations School of Pharmacy, University of Eastern Finland, Kuopio, Finland, Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland, Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- Antti Tanskanen
-
Affiliations Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden, National Institute for Health and Welfare, Helsinki, Finland
- Piia Lavikainen
-
Affiliation School of Pharmacy, University of Eastern Finland, Kuopio, Finland
- Marjaana Koponen
-
Affiliations School of Pharmacy, University of Eastern Finland, Kuopio, Finland, Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland
- Jari Tiihonen
-
Affiliations Department of Forensic Psychiatry, Niuvanniemi Hospital, Kuopio, Finland, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- Sirpa Hartikainen
-
Affiliations School of Pharmacy, University of Eastern Finland, Kuopio, Finland, Kuopio Research Centre of Geriatric Care, University of Eastern Finland, Kuopio, Finland, Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland
Competing Interests
JT has served as a consultant to Lundbeck, Organon, Janssen-Cilag, Eli Lilly, AstraZeneca, F. Hoffman-La Roche, and Bristol-Myers Squibb. He has received fees for giving expert opinions to Bristol-Myers Squibb and GlaxoSmithKline, lecture fees from Janssen-Cilag, Bristol-Myers Squibb, Eli Lilly, Pfizer, Lundbeck, GlaxoSmithKline, AstraZeneca and Novartis; and grant from Stanley Foundation. JT is a member of advisory board in AstraZeneca, Janssen-Cilag, and Otsuka. MK has received a personal research grant from Oy H. Lundbeck Ab foundation outside the submitted work. SH has received a lecturing fee from MSD. HT and AT have participated in research projects funded by Janssen with grants paid to the institution where they were employed. Other authors declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: AMT AV HT SH. Data curation: AMT AV HT AT MK. Formal analysis: AMT AV. Funding acquisition: AMT. Methodology: AMT AV HT AT MK PL. Project administration: AMT. Supervision: AMT. Visualization: AV. Writing – original draft: AMT HT SH. Writing – review & editing: AMT AV HT AT PL MK JT SH.